Key insights
- 10x Genomics (TXG) stock dropped 12% following a significant sale of shares by ARK Invest. This move, coupled with the company's cautious 2026 revenue growth guidance, raises concerns about institutional investor sentiment and future growth prospects, potentially pressuring the stock further.
Investing.com -- 10x Genomics (NASDAQ:TXG) shares fell 12% after ARK Invest sold more than 473,000 shares across its flagship exchange-traded funds, marking a notable shift in the firm’s positioning on the genomics toolmaker.
The sale by Cathie Wood’s investment firm raised concerns that other institutional investors may reduce their holdings, adding pressure to the stock. ARK Invest has been reallocating capital away from genomics toolmakers toward gene-editing platforms.
The sell-off comes as investors remain cautious about 10x Genomics’ growth prospects. The company previously issued muted revenue growth guidance for 2026, which has weighed on market expectations for the stock.
10x Genomics develops instruments and software for analyzing biological systems at single-cell resolution. The company serves researchers in oncology, immunology, and neuroscience.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.